Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has received European patent no. 1819698 from the European Patent Office for its new anti-cancer quinoxalinyl-piperazine compounds.
Subscribe to our email newsletter
The new patent covers several new quinoxalinyl-piperazine compounds, the process for their preparation, pharmaceutical composition, and a method for their producing an anti-proliferative effect.
Additionally, the new patent also covers the company’s pre-clinical compound RX-5902, which is currently being developed by the company and human trials are expected to start this year.
Rexahn Pharma president Rick Soni the issuance of this patent will enhance the commercial potential of RX-5902 in Europe .